Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT04231643
• Recruitment Status: Recruiting
• First Posted: January 18, 2020
• Last Update Posted: September 5, 2021
• Sponsor: University of California, San Diego
• Collaborator: National Institute on Drug Abuse (NIDA)
• Information provided by (Responsible Party): William Perry, University of California, San Diego

Study Description

Brief Summary:

Cannabis use is associated with younger age at onset of bipolar disorder, poor outcome, and more frequent manic episodes, but the effects of cannabis on cognition are less clear. Contrary to reports among non-psychiatric patients, cannabis may improve cognition among people with bipolar disorder. Nevertheless, no study to date has systematically tested the acute effects of cannabis on cognition in bipolar disorder. Therefore, the investigators propose to determine the effects of oral cannabinoid administration on cognitive domains relevant to bipolar disorder, e.g., arousal, decision making, cognitive control, inhibition, and temporal perception (sense of timing). In addition, the investigators will evaluate different doses of the two major components of cannabis, cannabidiol and ∆9-tetrahydrocannabinol, and compare them to placebo on these neurocognitive measures. The investigators will also test the effects of acute exposure to cannabinoids on cerebrospinal levels of anandamide and homovanillic acid - markers of endocannabinoid and dopamine activity in the brain, respectively. These studies will provide information that effectively bridges the fields of addiction and general psychiatry, informing treatment development for co-morbid substance abuse and psychiatric disorders.

Condition or disease	Intervention/treatment	Phase
Bipolar Disorder	Drug: Dronabinol; Drug: Epidiolex; Drug: Placebos	Early Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 144 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Basic Science
• Official Title: A Randomized, Controlled Trial of Cannabis in Bipolar Disorder Patients and Healthy Volunteers Evaluating Cognition and Endocannabinoid Levels
• Actual Study Start Date: September 1, 2021
• Estimated Primary Completion Date: February 28, 2023
• Estimated Study Completion Date: February 28, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Bipolar Disorder; adults with bipolar disorder	Drug: Dronabinol; one-time oral administration of 5 mg dronabinol; Drug: Epidiolex; one-time oral administration of 600 mg Epidiolex; Drug: Placebos; one-time oral administration of placebo
Active Comparator: Healthy Volunteers; adults with no psychiatric disease	Drug: Dronabinol; one-time oral administration of 5 mg dronabinol; Drug: Epidiolex; one-time oral administration of 600 mg Epidiolex; Drug: Placebos; one-time oral administration of placebo

Outcome Measures

Primary Outcome Measures :

1. Score on Iowa Gambling Task [ Time Frame: one day ]
   This is an experimental measure and not a scale with specific anchor points. Lower scores reflect increased risk-taking
2. Score on Progressive Ratio Test [ Time Frame: one day ]
   This is an experimental measure and not a scale with specific anchor points. Higher scores indicate increased willingness to work for a reward
3. Scores on Probabilistic Learning Task [ Time Frame: one day ]
   This is an experimental measure and not a scale with specific anchor points. Measures decision-making strategies such as win-stay, lose-shift.
4. Scores on Continuous Performance Task [ Time Frame: one day ]
   This is an experimental measure and not a scale with specific anchor points. Higher scores reflect better attention and ability to discriminate important information from unimportant information
5. Percent Prepulse Inhibition (PPI) [ Time Frame: one day ]
   This is a physiological measure and not a scale with specific anchor points. Higher percent PPI reflects better sensorimotor gating
6. motor activity in the human Behavioral Pattern Monitor [ Time Frame: one day ]
   This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via amount of motor activity as measured by a wearable accelerometer. Increased motor activity reflects increased tendency to engage in exploratory behavior.
7. object interactions in the human Behavioral Pattern Monitor [ Time Frame: one day ]
   This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via video ratings that quantify number of interactions with novel objects. Increased object interactions reflects increased novelty-seeking behavior.
8. cerebrospinal fluid levels of anandamide [ Time Frame: one day ]
   Reflects increased availability of the endogenous cannabinoid anandamide in the brain

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Participants will be asked about which gender they identify with
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. For subjects in BD group, DSM-5 criteria for Bipolar Disorder as determined by the Structured Clinical Interview for DSM-5 (SCID).
2. Young Mania Rating Scale (YMRS) < 12.
3. Infrequent cannabis use as defined by a history of cannabis use but <5 times per month [37] and no use in the past 14 days prior to experimental sessions.

Exclusion Criteria:

1. Hamilton Depression Rating Scale (HDRS) score > 10.
2. Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation ("I wished I were dead". "I wanted to hurt myself") will be completed. Should any of these items be answered affirmatively, e.g., the subject has endorsed these items for at least 1-2 days in the last week, the subject will not be enrolled in the study.
3. The Substance Abuse Module of the Diagnostic Interview Schedule for DSM-5 will be administered to exclude individuals with current substance use disorders.
4. Clinically significant or unstable medical condition. Subjects will undergo a medical evaluation (H&P, toxicology screening, and for females of childbearing potential, pregnancy testing (utilizing a human chorionic gonadotropin (hCG) urine test). Individuals with significant cardiovascular disease (e.g., angina, myocardial infarction or stroke), hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (e.g., asthma, COPD), will be excluded. With respect to cardiovascular and pulmonary status, a clinician will screen participants with a tool developed for this purpose (Appendix 3 Cardiopulmonary Screen). Hepatic and renal disease will be evaluated with liver and renal function laboratory tests. Females who are pregnant or lactating will be excluded.
5. Infections - evidence of skin infection at lumbar puncture site.
6. To avoid confounding of cognitive testing, a neurological disorder such as seizures, stroke, Parkinson's disease, dementia, or a history of head injury with loss of consciousness for at least 15 minutes will be excluded.
7. Unwilling to refrain from driving or operate heavy machinery for four hours after consuming study medication. This criterion is consistent with current expert recommendations on driving following the use of cannabis.
8. Additionally, because the hBPM paradigm requires participants to be ambulatory, those who cannot ambulate independently (e.g., require a wheelchair) or those who have a motor disease (e.g., multiple sclerosis, cerebral palsy) will be excluded.
9. A previous adverse reaction to cannabinoids will be cause for exclusion as will a historical diagnosis of cannabis use disorder.
10. Positive result on Draeger 5000 test indicating recent cannabis use.
11. Unwillingness to prevent pregnancy during the cannabinoid administration portion of the study (using birth control in female participants of child-bearing age) Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc.
12. Any active opportunistic infection or malignant condition requiring acute treatment.

Contacts and Locations

Contacts

Contact: Nathan Wood, MA; 6195436575; n2wood@ucsd.edu

Locations

United States, California

UC San Diego Medical Center; Recruiting

San Diego, California, United States, 92103

Contact: Nathan Wood, MA 619-543-6575 n2wood@ucsd.edu

Sponsors and Collaborators

University of California, San Diego

National Institute on Drug Abuse (NIDA)

Investigators

• Principal Investigator: William Perry, PhD; UCSD

More Information

• Responsible Party: William Perry, Professor in Residence of Psychiatry, University of California, San Diego
• ClinicalTrials.gov Identifier: NCT04231643
• Other Study ID Numbers: 180356; R01DA043535 ( U.S. NIH Grant/Contract )
• First Posted: January 18, 2020
• Last Update Posted: September 5, 2021
• Last Verified: September 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by William Perry, University of California, San Diego:

cannabidiol; THC

Additional relevant MeSH terms:

Bipolar Disorder; Bipolar and Related Disorders; Mental Disorders; Dronabinol; Epidiolex; Hallucinogens; Physiological Effects of Drugs; Psychotropic Drugs; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Anticonvulsants